SmithKline Beecham Recognizes New Research by Oncology Fellows in Third-Annual Forum

Strategic Insights -

SmithKline Beecham, a leading healthcare company, announced the winners of the 1999 SmithKline Beecham National Gynecologic and Medical Oncology Fellows Forums. Eight medical and gynecologic oncology fellows were awarded grants to present their research at a national medical oncology meeting. The program, now in its third year, aims to recognize promising cancer research by new medical and gynecologic practitioners. This year's winners presented research on various topics, including ovarian cancer, CD40 expression, and chemotherapy-induced apoptosis. The company has made a strong commitment to furthering cancer research and provides a unique opportunity for the newest members of the oncology community to interact with thought-leaders and network with their colleagues.

Key Takeaways:

  • Eight oncology fellows from around the country were awarded grants to present their research at a national medical oncology meeting.
  • The program, now in its third year, aims to recognize promising cancer research by new medical and gynecologic practitioners.
  • The winners presented research on topics such as ovarian cancer, CD40 expression, and chemotherapy-induced apoptosis.
  • The program was established to provide a platform for new oncology leaders to share their research and network with peers.
  • SmithKline Beecham has supported over 200 clinical trials with Hycamtin and is currently investigating use of Hycamtin alone and in combination for various tumor types.
  • The company has a number of compounds under development, including Bexxar for the treatment of non-Hodgkin's lymphoma.
  • The SmithKline Beecham National Gynecologic and Medical Oncology Fellows Forums were held in February and March 1999, with over 100 abstracts received and 30 selected for presentation in each category.
  • Faculty co-chairs for the forums included Distinguished Oncologists such as Beth Y. Karlan, M.D. and Maurie Markman, M.D.

Statistics:

  • Eight oncology fellows received grants to present their research.
  • Over 100 abstracts were received for the forums, with 30 selected for presentation in each category.
  • SmithKline Beecham has supported over 200 clinical trials with Hycamtin.
  • The company has a number of compounds under development, including Bexxar for the treatment of non-Hodgkin's lymphoma.

Sources:

  • M2 PressWire: "SmithKline Beecham: SmithKline Beecham recognizes new research by oncology fellows in third-annual forum", M2 COMMUNICATIONS LTD, 26 March 1999.
  • SmithKline Beecham Website: "SmithKline Beecham Oncology", SmithKline Beecham, 1999.